On September 19, ISPIRE (ISPR.US), a tech company known as "Fog Hemp Technology," released its fiscal year 2023 report. The performance report reveals that ISPIRE experienced a revenue growth of 31.2% in the 2023 fiscal year, reaching a total of $115.6 million.
Michael Wang, Co-CEO of ISPIRE, has described the 2023 fiscal year as a significant milestone for the company. Revenue from CBD and e-cigarette products saw impressive growth of 100.4% and 10.9% respectively, contributing to an overall revenue increase of 31.2%. This growth was primarily driven by a doubling of income from ISPIRE's CBD vaporizer products in the United States and increased sales of e-cigarette products in Europe.
He stated that the key to this success is ISPIRE's multi-pronged strategy: expanding the sales of CBD vaporizer products to provide innovative solutions for both medical and recreational sectors.
He also stated that ISPIRE's factory in California, United States, will launch its first fully automated assembly line by the end of 2023. Furthermore, ISPIRE is actively considering Southeast Asia as a potential manufacturing hub for future business, aiming to further optimize production capacity.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
